Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 10:23 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT00529048 · Registry updated: 2009-10-20

Condition / research focus: Incretin Effect
Sponsor: Herlev Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2007-10. Completion: 2009-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral Glucose Tolerance Test (other)
Isoglycemic clamp (other)
Gastric emptying rate (other)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Endokrinologisk afd. J, Herlev Hospital
Herlev, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

ClinicalTrials.gov · NCT00259727 · Registry updated: 2009-09-30

Condition / research focus: Diabetes; HIV Infections; Insulin Resistance
Sponsor: US Department of Veterans Affairs
Countries with listed sites: United States
Registry dates and results: Start: 2006-01. Completion: 2008-09 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

VA Medical Center, San Francisco
San Francisco, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

GLP-1 - Regulatory Mechanism of Postprandial Glycemia

ClinicalTrials.gov · NCT00980083 · Registry updated: 2009-09-18

Condition / research focus: Healthy Subjects; Gastric Emptying
Sponsor: Ludwig-Maximilians - University of Munich
Countries with listed sites: Germany
Registry dates and results: Start: 2004-10. Completion: 2007-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saline (drug)
Exendin(9-39)amide (drug)

Where the study takes place — 1 listed sites

Department of Internal Medicine II, University of Munich
Munich, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Randomized Trial of ERCP Then Laparoscopic Cholecystectomy vs. Laparoscopic Cholecystectomy Plus Laparoscopic Common Bile Duct Exploration in Patients With Likely Choledocholithiasis

ClinicalTrials.gov · NCT00807729 · Registry updated: 2009-09-03

Condition / research focus: Choleclithiasis; Common Bile Duct Stones
Sponsor: University of California, San Francisco
Countries with listed sites: United States
Registry dates and results: Start: 1997-01. Completion: 2007-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ERCP (procedure) — also listed as: ERCP/ laparoscopic cholecystectomy
LapCBDE (procedure) — also listed as: Laparoscopic common bile duct exploration

Where the study takes place — 1 listed sites

San Francisco General Hospital
San Francisco, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Incretin Physiology Associated With Steroid Hormone Treatment

ClinicalTrials.gov · NCT00713440 · Registry updated: 2009-08-06

Condition / research focus: Type 2 Diabetes Mellitus; Steroids
Sponsor: Glostrup University Hospital, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2008-07. Completion: 2009-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol (other) — also listed as: Prednisolone, Paracetamol

Where the study takes place — 1 listed sites

Clinical Physiology Department; Glostrup Univesity Hospital
Glostrup Municipality, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Glucagon Modulation of Ghrelin Secretion

ClinicalTrials.gov · NCT00929812 · Registry updated: 2009-06-30

Condition / research focus: Healthy Subjects; Obesity; Diabetes Mellitus, Type 1
Sponsor: Charite University, Berlin, Germany
Countries with listed sites: Germany
Registry dates and results: Start: 2006-06. Completion: 2009-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon hydrochloride (GlucaGen®) (drug) — also listed as: GlucaGen® (Novo Nordisk Pharma, MA:28288.00.00)
NaCl 0.9% (drug)

Where the study takes place — 1 listed sites

Charite Campus Benjamin Franklin
Berlin, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

PET-CT Scan Method to Monitor Pancreatic B-Cell Loss in Diabetes Mellitus

ClinicalTrials.gov · NCT00633763 · Registry updated: 2009-05-29

Condition / research focus: Type1 Diabetes Mellitus
Sponsor: University of California, Irvine
Countries with listed sites: United States
Registry dates and results: Start: 2008-02. Completion: 2008-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

18F-fallypride (drug)
18F-fallypride (drug)

Where the study takes place — 1 listed sites

University of California Irvine Medical Center
Orange, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers

ClinicalTrials.gov · NCT00434772 · Registry updated: 2009-05-28

Condition / research focus: Hypoglycemia
Sponsor: Shaare Zedek Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2007-12. Completion: 2009-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon (drug)

Where the study takes place — 1 listed sites

Share Zedek Medical Center
Jerusalem, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

To Evaluate the Response to Glucagon During Hypoglycemia

ClinicalTrials.gov · NCT00817271 · Registry updated: 2009-05-07

Condition / research focus: Type 2 Diabetes
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2009-02. Completion: 2009-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AZD1656 (drug)
Glucagon (drug)

Where the study takes place — 1 listed sites

Research Site
Chula Vista, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans

ClinicalTrials.gov · NCT00876213 · Registry updated: 2009-04-06

Condition / research focus: Diabetes
Sponsor: Hvidovre University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2007-03. Completion: 2008-06 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Hvidovre Hospital
Hvidovre, Hvidovre, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT00655603 · Registry updated: 2009-04-06

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: No country reported
Registry dates and results: Start: 2008-03. Completion: 2009-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Infusion of native hormones from the pancreas and gut (GLP-1) (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)

ClinicalTrials.gov · NCT00862589 · Registry updated: 2009-03-18

Condition / research focus: Hyperglycemia; Hyperglucagonemia; Glucose Intolerance
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-10. Completion: 2007-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 infusion (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients

ClinicalTrials.gov · NCT00859079 · Registry updated: 2009-03-10

Condition / research focus: Diabetes Mellitus Type 2; Hyperglycemia
Sponsor: Medical University of Graz
Countries with listed sites: Austria
Registry dates and results: Start: 2006-06. Completion: 2007-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 (drug) — also listed as: GLP-1 infusion (CLINALFA, Laeufelingen, Switzerland)
Human regular insulin intravenously (drug) — also listed as: Insulin Actrapid, NovoNordisk, Denmark

Where the study takes place — 1 listed sites

Medical University of Graz, Department for Internal Medicine
Graz, Austria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

ClinicalTrials.gov · NCT00732602 · Registry updated: 2009-02-13

Condition / research focus: Diabetes Mellitus
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2008-01. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GIP-infusion (other)
Sodium-chloride (other)
GLP-2 infusion (other)

Where the study takes place — 1 listed sites

University Hospital, Gentofte
Hellerup, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Glycemic Rises After Waking Up In Response To An Alarm Clock In Type 1-Diabetic Patients Analysed With Continuous Glucose Monitoring (GlucoDay®)

ClinicalTrials.gov · NCT00740012 · Registry updated: 2008-09-29

Condition / research focus: Stress; Type 1 Diabetes
Sponsor: Diabeteszentrum Bad Lauterberg im Harz
Countries with listed sites: Germany
Registry dates and results: Start: 2007-03. Completion: 2008-09 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Continuous glucose monitoring (other) — also listed as: Gluco Day S (Menarini Diagnostics)
alarm- clock intervention, patient perform blood glucose self monitoring (other) — also listed as: Ordinary alarm clock
nurse intervention (other) — also listed as: professional night nurses
Taking the patients pulse (other) — also listed as: Pulse measurment
Venous blood drawing (other) — also listed as: venous blood drawing from an intravenous catheter
Other capillary sample (other) — also listed as: laboratory method (EBIOS, Eppendorf, Hamburg, Germany)

Where the study takes place — 1 listed sites

Diabeteszentrum Bad Lauterberg im Harz
Bad Lauterberg im Harz, Lower Saxony, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

GLP-1 Infusion and Long-Time Fasting

ClinicalTrials.gov · NCT00285896 · Registry updated: 2008-07-11

Condition / research focus: Type 2 Diabetes
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2005-12. Completion: 2007-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon-like-peptide-1 (7-36) amide (drug) — also listed as: GLP-1
Placebo (drug)

Where the study takes place — 1 listed sites

Department of pharmacology, Aarhus university and Medical department M, Aarhus University hospital
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes

ClinicalTrials.gov · NCT00704795 · Registry updated: 2008-06-26

Condition / research focus: Hyperglucagonemia; Hyperglycemia; Diabetes Mellitus
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2008-06. Completion: 2009-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral glucose tolerance test (other) — also listed as: OGTT, 50 g-OGTT
Isoglycemic iv glucose infusion (other) — also listed as: Isoglycemic IVGTT

Where the study takes place — 1 listed sites

Gentofte University Hospital
Hellerup, Hellerup, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia

ClinicalTrials.gov · NCT00418288 · Registry updated: 2008-06-10

Condition / research focus: Type 2 Diabetes; Stroke; Myocardial Infarction
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2007-01. Completion: 2008-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon-like-peptide-1 (drug)
placebo (drug)

Where the study takes place — 1 listed sites

Department of pharmacology, Aarhus university
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome

ClinicalTrials.gov · NCT00673751 · Registry updated: 2008-05-07

Condition / research focus: Short Bowel Syndrome
Sponsor: Glostrup University Hospital, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: Not reported. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-2 (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Glostrup University Hospital
Glostrup Municipality, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Diagnosis and Treatment of Pheochromocytoma

ClinicalTrials.gov · NCT00001229 · Registry updated: 2008-03-04

Condition / research focus: Pheochromocytoma
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Countries with listed sites: United States
Registry dates and results: Start: 1988-10. Completion: 2001-01 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 10:23 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase not reported / not applicableCompletedOBSERVATIONAL

Quantification of the Incretin Effect in Healthy Subjects and Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT00529048 · Registry updated: 2009-10-20

Condition / research focus: Incretin Effect
Sponsor: Herlev Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2007-10. Completion: 2009-09 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral Glucose Tolerance Test (other)
Isoglycemic clamp (other)
Gastric emptying rate (other)

Where the study takes place — 1 listed sites

Endokrinologisk afd. J, Herlev Hospital
Herlev, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

ClinicalTrials.gov · NCT00259727 · Registry updated: 2009-09-30

Condition / research focus: Diabetes; HIV Infections; Insulin Resistance
Sponsor: US Department of Veterans Affairs
Countries with listed sites: United States
Registry dates and results: Start: 2006-01. Completion: 2008-09 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

VA Medical Center, San Francisco
San Francisco, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

GLP-1 - Regulatory Mechanism of Postprandial Glycemia

ClinicalTrials.gov · NCT00980083 · Registry updated: 2009-09-18

Condition / research focus: Healthy Subjects; Gastric Emptying
Sponsor: Ludwig-Maximilians - University of Munich
Countries with listed sites: Germany
Registry dates and results: Start: 2004-10. Completion: 2007-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Saline (drug)
Exendin(9-39)amide (drug)

Where the study takes place — 1 listed sites

Department of Internal Medicine II, University of Munich
Munich, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Randomized Trial of ERCP Then Laparoscopic Cholecystectomy vs. Laparoscopic Cholecystectomy Plus Laparoscopic Common Bile Duct Exploration in Patients With Likely Choledocholithiasis

ClinicalTrials.gov · NCT00807729 · Registry updated: 2009-09-03

Condition / research focus: Choleclithiasis; Common Bile Duct Stones
Sponsor: University of California, San Francisco
Countries with listed sites: United States
Registry dates and results: Start: 1997-01. Completion: 2007-11 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

ERCP (procedure) — also listed as: ERCP/ laparoscopic cholecystectomy
LapCBDE (procedure) — also listed as: Laparoscopic common bile duct exploration

Where the study takes place — 1 listed sites

San Francisco General Hospital
San Francisco, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Incretin Physiology Associated With Steroid Hormone Treatment

ClinicalTrials.gov · NCT00713440 · Registry updated: 2009-08-06

Condition / research focus: Type 2 Diabetes Mellitus; Steroids
Sponsor: Glostrup University Hospital, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2008-07. Completion: 2009-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol (other) — also listed as: Prednisolone, Paracetamol

Where the study takes place — 1 listed sites

Clinical Physiology Department; Glostrup Univesity Hospital
Glostrup Municipality, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Glucagon Modulation of Ghrelin Secretion

ClinicalTrials.gov · NCT00929812 · Registry updated: 2009-06-30

Condition / research focus: Healthy Subjects; Obesity; Diabetes Mellitus, Type 1
Sponsor: Charite University, Berlin, Germany
Countries with listed sites: Germany
Registry dates and results: Start: 2006-06. Completion: 2009-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon hydrochloride (GlucaGen®) (drug) — also listed as: GlucaGen® (Novo Nordisk Pharma, MA:28288.00.00)
NaCl 0.9% (drug)

Where the study takes place — 1 listed sites

Charite Campus Benjamin Franklin
Berlin, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

PET-CT Scan Method to Monitor Pancreatic B-Cell Loss in Diabetes Mellitus

ClinicalTrials.gov · NCT00633763 · Registry updated: 2009-05-29

Condition / research focus: Type1 Diabetes Mellitus
Sponsor: University of California, Irvine
Countries with listed sites: United States
Registry dates and results: Start: 2008-02. Completion: 2008-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

18F-fallypride (drug)
18F-fallypride (drug)

Where the study takes place — 1 listed sites

University of California Irvine Medical Center
Orange, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Glucagon in the Treatment of Hypoglycemia in Newborn Infants of Diabetic Mothers

ClinicalTrials.gov · NCT00434772 · Registry updated: 2009-05-28

Condition / research focus: Hypoglycemia
Sponsor: Shaare Zedek Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2007-12. Completion: 2009-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon (drug)

Where the study takes place — 1 listed sites

Share Zedek Medical Center
Jerusalem, Israel
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

To Evaluate the Response to Glucagon During Hypoglycemia

ClinicalTrials.gov · NCT00817271 · Registry updated: 2009-05-07

Condition / research focus: Type 2 Diabetes
Sponsor: AstraZeneca
Countries with listed sites: United States
Registry dates and results: Start: 2009-02. Completion: 2009-04 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AZD1656 (drug)
Glucagon (drug)

Where the study takes place — 1 listed sites

Research Site
Chula Vista, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Amylin and Glucagon-Like Peptide-1 (GLP-1): Influence on Gastric Emptying, Appetite and Food Intake in Humans

ClinicalTrials.gov · NCT00876213 · Registry updated: 2009-04-06

Condition / research focus: Diabetes
Sponsor: Hvidovre University Hospital
Countries with listed sites: Denmark
Registry dates and results: Start: 2007-03. Completion: 2008-06 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Hvidovre Hospital
Hvidovre, Hvidovre, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Influence of Glucagon Inhibition in Relation to the Anti-Diabetic Effect of Glucagon-Like Peptide-1 (GLP-1) in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT00655603 · Registry updated: 2009-04-06

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: No country reported
Registry dates and results: Start: 2008-03. Completion: 2009-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Infusion of native hormones from the pancreas and gut (GLP-1) (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)

ClinicalTrials.gov · NCT00862589 · Registry updated: 2009-03-18

Condition / research focus: Hyperglycemia; Hyperglucagonemia; Glucose Intolerance
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-10. Completion: 2007-03 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 infusion (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients

ClinicalTrials.gov · NCT00859079 · Registry updated: 2009-03-10

Condition / research focus: Diabetes Mellitus Type 2; Hyperglycemia
Sponsor: Medical University of Graz
Countries with listed sites: Austria
Registry dates and results: Start: 2006-06. Completion: 2007-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-1 (drug) — also listed as: GLP-1 infusion (CLINALFA, Laeufelingen, Switzerland)
Human regular insulin intravenously (drug) — also listed as: Insulin Actrapid, NovoNordisk, Denmark

Where the study takes place — 1 listed sites

Medical University of Graz, Department for Internal Medicine
Graz, Austria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

ClinicalTrials.gov · NCT00732602 · Registry updated: 2009-02-13

Condition / research focus: Diabetes Mellitus
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2008-01. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GIP-infusion (other)
Sodium-chloride (other)
GLP-2 infusion (other)

Where the study takes place — 1 listed sites

University Hospital, Gentofte
Hellerup, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Glycemic Rises After Waking Up In Response To An Alarm Clock In Type 1-Diabetic Patients Analysed With Continuous Glucose Monitoring (GlucoDay®)

ClinicalTrials.gov · NCT00740012 · Registry updated: 2008-09-29

Condition / research focus: Stress; Type 1 Diabetes
Sponsor: Diabeteszentrum Bad Lauterberg im Harz
Countries with listed sites: Germany
Registry dates and results: Start: 2007-03. Completion: 2008-09 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Continuous glucose monitoring (other) — also listed as: Gluco Day S (Menarini Diagnostics)
alarm- clock intervention, patient perform blood glucose self monitoring (other) — also listed as: Ordinary alarm clock
nurse intervention (other) — also listed as: professional night nurses
Taking the patients pulse (other) — also listed as: Pulse measurment
Venous blood drawing (other) — also listed as: venous blood drawing from an intravenous catheter
Other capillary sample (other) — also listed as: laboratory method (EBIOS, Eppendorf, Hamburg, Germany)

Where the study takes place — 1 listed sites

Diabeteszentrum Bad Lauterberg im Harz
Bad Lauterberg im Harz, Lower Saxony, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

GLP-1 Infusion and Long-Time Fasting

ClinicalTrials.gov · NCT00285896 · Registry updated: 2008-07-11

Condition / research focus: Type 2 Diabetes
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2005-12. Completion: 2007-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon-like-peptide-1 (7-36) amide (drug) — also listed as: GLP-1
Placebo (drug)

Where the study takes place — 1 listed sites

Department of pharmacology, Aarhus university and Medical department M, Aarhus University hospital
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes

ClinicalTrials.gov · NCT00704795 · Registry updated: 2008-06-26

Condition / research focus: Hyperglucagonemia; Hyperglycemia; Diabetes Mellitus
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2008-06. Completion: 2009-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral glucose tolerance test (other) — also listed as: OGTT, 50 g-OGTT
Isoglycemic iv glucose infusion (other) — also listed as: Isoglycemic IVGTT

Where the study takes place — 1 listed sites

Gentofte University Hospital
Hellerup, Hellerup, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia

ClinicalTrials.gov · NCT00418288 · Registry updated: 2008-06-10

Condition / research focus: Type 2 Diabetes; Stroke; Myocardial Infarction
Sponsor: University of Aarhus
Countries with listed sites: Denmark
Registry dates and results: Start: 2007-01. Completion: 2008-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucagon-like-peptide-1 (drug)
placebo (drug)

Where the study takes place — 1 listed sites

Department of pharmacology, Aarhus university
Aarhus, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome

ClinicalTrials.gov · NCT00673751 · Registry updated: 2008-05-07

Condition / research focus: Short Bowel Syndrome
Sponsor: Glostrup University Hospital, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: Not reported. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-2 (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Glostrup University Hospital
Glostrup Municipality, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Diagnosis and Treatment of Pheochromocytoma

ClinicalTrials.gov · NCT00001229 · Registry updated: 2008-03-04

Condition / research focus: Pheochromocytoma
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Countries with listed sites: United States
Registry dates and results: Start: 1988-10. Completion: 2001-01 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →